PANTOPRAZOLE AND ALGINATES ON THE FIRST DAYS OF TREATMENT FOR GASTROESOPHAGEAL REFLUX DISEASE: ADVANTAGES OF COADMINISTRATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

When treating patients with gastroesophageal reflux disease, it is very important to eliminate its signs on the first days of therapy since this improves patient adherence to treatment. The antisecretory effect of proton pump inhibitors develops comparatively slowly and their combination with alginates allows heartburn to be eliminated within the first 24 hours of therapy.

Full Text

Restricted Access

About the authors

D. Bordin

Central Research Institute of Gastroenterology; Clinical Research and Practical Center, Moscow Healthcare Department

MD

O. Yanova

Central Research Institute of Gastroenterology; Clinical Research and Practical Center, Moscow Healthcare Department

Email: o.yanova@mknc.ru
Candidate of Medical Sciences

O. Berezina

Central Research Institute of Gastroenterology; Clinical Research and Practical Center, Moscow Healthcare Department

E. Treiman

Central Research Institute of Gastroenterology; Clinical Research and Practical Center, Moscow Healthcare Department

References

  1. Vakil N., van Zanden S., Kahrilas P. et al. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus // Am. J. Gastroenterol. - 2006; 101: 1900-20.
  2. Лазебник Л.Б., Бордин Д.С., Машарова А.А. Современное понимание гастроэзофагеальной рефлюксной болезни: от Генваля к Монреалю // Экспер. и клин. гастроэнтерол. - 2007; 5: 4-10.
  3. Kulig M., Leodolter A., Vieth M. et al. Quality of life in relation to symptoms in patient with gastro-oesophageal reflux disease-ananalysis based on the ProGERD initiative // Aliment. Pharm. Ther. - 2003; 18: 767-76.
  4. Becher A., El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease // Aliment. Pharmacol. Ther. -2011; 34: 618-27.
  5. Dent J., Armstrong D., Delaney B. et al. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs // Gut. - 2004; 53 (Suppl. 4): 1-24.
  6. Бордин Д.С. «Кислотный карман» как патогенетическая основа и терапевтическая мишень при гастроэзофагеальной рефлюксной болезни // Тер. арх. - 2014; 2: 76-80.
  7. Van Pinxteren B., Numan M., Bonis P. et al. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease // Cochrane Database Syst. Rev. - 2004; 4: CD002095.
  8. Holtmann G., Adam B., Liebregts T. Review article: the patient with gastro-oesophageal reflux disease--lifestyle advice and medication // Aliment. Pharmacol. Ther. - 2004; 20: 24-7.
  9. Donnellan C., Preston C., Moayyedi P. et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Cochrane Review). In: The Cochrane Library 2009 Is. 2. Chichester, UK: John Wiley and Sons, Ltd.
  10. Blume H., Donath F., Warnke A. et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors // Drug. Saf. - 2006; 29 (9): 769-84.
  11. Бордин Д.С. Как выбрать ингибитор протонной помпы больному ГЭРБ? // Экспер. и клин. гастроэнтерол. - 2010; 2: 53-8.
  12. McQuaid K., Laine L. Купирование изжоги с помощью ингибиторов протонной помпы: систематический обзор и метаанализ клинических испытаний // Клин. гастроэнтерол. и гепатол. (русское изд.). - 2008; 3: 184-92.
  13. Sachs G., Shin J., Vagin O. et al. The gastric H, K ATPase as a drug target: past, present, and future // J. Clin. Gastroenterol. - 2007; 41 (2): 226-42.
  14. Лазебник Л.Б., Бордин Д.С., Машарова и др. Факторы, влияющие на эффективность лечения гастроэзофагеальной рефлюксной болезни ингибиторами протонного насоса // Тер. арх. - 2012; 2: 16-21.
  15. Бордин Д.С., Машарова А.А., Фирсова Л.Д. и др. Оценка скорости начала действия и купирования изжоги при однократном приеме альгинатов у больных ГЭРБ // Экспер. и клин. гастроэнтерол. - 2009; 4: 83-91.
  16. Strugala V., Dettmar P., Sarratt K. et al. Randomized, controlled, crossover trial to investigate times to onset of the perception of soothing and cooling by over-the-counter heartburn treatments // J. Int. Med. Res. - 2010; 38: 449-57.
  17. Kwiatek M., Roman S., Fareeduddin A. et al. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial «acid pocket» in symptomatic GERD patients // Aliment. Pharmacol. Ther. -2011; 34 (1): 59-66.
  18. Янова О.Б., Березина О.И., Ким В.А. Эффективность нового альгинат-антацидного препарата Гевискон Двойное Действие® в устранении постпран-диального рефлюкса // Лечащий врач. - 2013; 4: 74-6.
  19. Kapadia C., Mane V. Raft-forming agents: antireflux formulations // Drug. Dev. Ind. Pharm. - 2007; 33 (12): 1350-61.
  20. Лазебник Л.Б., Бордин Д.С., Машарова А.А. и др. Восстановление качества жизни устранением и предотвращением изжоги альгинатом»: результаты многоцентрового исследования «ВИА АПИА» // Экспер. и клин. гастроэнтерол. - 2010; 6: 70-6.
  21. Chiu C.-T., Hsu C.-M., Wang C.-C. et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease // Aliment. Pharmacol. Ther. - 2013; 38 (9): 1054-64.
  22. Dettmar P., Hampson F., Jain A. et al. Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole // Indian J. Med. Res. - 2006; 123 (4): 517-24.
  23. Lundell L., Dent J., Bennett J. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification // Gut. - 1999; 45 (2): 172-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies